A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

Exclusion Criteria

• •Current forms of psoriasis other than chronic plaque-type
• •Current drug induced psoriasis
• •History of hypersensitivity or allergy to the IMP or its excipients
• •History of recurrent or medically important infections requiring intervention and/or systemic treatment in the last 12 months, including infections with e.g. candida and Staphylococcus aureus
• •History of or any signs of lymphoproliferative disease, or a known malignancy or a history of malignancy within the previous 5 years (with the exception of basal cell or squamous cell carcinoma of the skin that had been fully excised with no evidence of recurrence)
• •Autoimmune disease of relevance
• •Inflammatory Bowel Disease requiring treatment within the past 12 months
• •Clinically significant heart condition which is not well controlled by current therapy, as assessed by the Investigator
• •Significantly immunocompromised subject
• •Blood pressure out of range
• •Laboratory values out of range, including ALT, AST, eGFR
• •Positive to HIV, hepatitis B, hepatitis C or tuberculosis
• •Recent previous psoriasis treatments, within defined wash-out periods
• •Prior exposure to systemic psoriasis treatments with anti-IL-17 biological therapies
• •Live vaccination within defined time restrictions
• •Inability or unwillingness to limit ultraviolet (UV) light exposure during the course of the study
• •Pregnancy, breast feeding
• •Drug and/or alcohol abuse or dependence